Literature DB >> 20173494

Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases.

Ali Dastranj Tabrizi1, Steve E Kalloger, Martin Köbel, Jane Cipollone, Calvin D Roskelley, Erika Mehl, C Blake Gilks.   

Abstract

Primary ovarian mucinous carcinomas of the intestinal type are uncommon and earlier reports have included cases diagnosed according to older, less stringent, criteria (which would now be considered borderline tumors) and variable numbers of cases of metastatic adenocarcinoma. This study was conducted to identify all cases of primary mucinous carcinoma of the ovary in a population-based registry, diagnosed according to WHO 2003 criteria, and to characterize their histologic features, immunohistochemical expression profile, and outcome. Thirty-one cases of primary ovarian mucinous carcinoma were included in this study. Immunostaining for 33 markers was performed. Mean age of the patients was 55.4+/-13.5 years. Thirty tumors were stage I or II at presentation. Twenty-six of 31 (83.9%) tumors had expansile stromal invasion, 4 of 31 (12.9%) showed destructive invasion, and 1 of 31 (3.2%) had anaplastic carcinoma in a mural nodule. All cases with destructive invasion showed grade 3 nuclear atypia whereas only 3 of 26 (11.5%) cases with expansile invasion had grade 3 nuclear atypia (P=0.0003). At follow-up, 6 of 26 patients (23.1%) with tumors showing expansile invasion experienced a recurrence, compared with 1 of 4 patients (25%) with destructive invasion and the single patient (100%) with anaplastic carcinoma. There was CK7 positivity in 26 of 31 cases (86.7%), and CK20 and Cdx-2 were each positive in 33.3% of cases. D2-40, calretinin, mesothelin, CA-125, Pax-8, TTF, and WT1 were completely negative in all cases. NHERF1 staining was present in 19 of 26 cases (73%) and its expression was associated with poor prognosis (P=0.05). Our findings support current diagnostic criteria for primary ovarian mucinous carcinoma, that is, the presence of expansile invasion, in the absence of destructive invasion, warrants a diagnosis of carcinoma. A large majority of mucinous carcinomas show only an expansile pattern of invasion and are confined to the pelvis at diagnosis.

Entities:  

Mesh:

Year:  2010        PMID: 20173494     DOI: 10.1097/PGP.0b013e3181bbbcc1

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  22 in total

Review 1.  [Morphology of secondary ovarian tumors and metastases].

Authors:  L-C Horn; J Einenkel; R Handzel; A K Höhn
Journal:  Pathologe       Date:  2014-07       Impact factor: 1.011

Review 2.  New roles of the Na+/H+ exchange regulatory factor 1 scaffolding protein: a review.

Authors:  Adrienne M Bushau-Sprinkle; Eleanor D Lederer
Journal:  Am J Physiol Renal Physiol       Date:  2020-01-27

3.  The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma.

Authors:  Jane A Cipollone; Marcia L Graves; Martin Köbel; Steve E Kalloger; Tak Poon; C Blake Gilks; Kelly M McNagny; Calvin D Roskelley
Journal:  Clin Exp Metastasis       Date:  2012-01-20       Impact factor: 5.150

4.  IMP3 is upregulated in primary ovarian mucinous carcinoma and promotes tumor progression.

Authors:  Qin Zhu; Yuqing Qu; Qiongyan Zhang; Linghui Lu; Weiwei Weng; Hao Zhang; Lihong Zhang; Yan Ning; Yiqin Wang
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

Review 5.  Role of the PDZ-scaffold protein NHERF1/EBP50 in cancer biology: from signaling regulation to clinical relevance.

Authors:  J Vaquero; T H Nguyen Ho-Bouldoires; A Clapéron; L Fouassier
Journal:  Oncogene       Date:  2017-01-09       Impact factor: 9.867

Review 6.  Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Authors:  W Glenn McCluggage; Meagan J Judge; Blaise A Clarke; Ben Davidson; C Blake Gilks; Harry Hollema; Jonathan A Ledermann; Xavier Matias-Guiu; Yoshiki Mikami; Colin J R Stewart; Russell Vang; Lynn Hirschowitz
Journal:  Mod Pathol       Date:  2015-06-19       Impact factor: 7.842

7.  PAX2, PAX8 and CDX2 Expression in Metastatic Mucinous, Primary Ovarian Mucinous and Seromucinous Tumors and Review of the Literature.

Authors:  D Ates Ozdemir; A Usubutun
Journal:  Pathol Oncol Res       Date:  2016-01-21       Impact factor: 3.201

8.  NHERF1 acts as a molecular switch to program metastatic behavior and organotropism via its PDZ domains.

Authors:  Rosa Angela Cardone; Maria Raffaella Greco; Mattia Capulli; Edward J Weinman; Giovanni Busco; Antonia Bellizzi; Valeria Casavola; Ester Antelmi; Barbara Ambruosi; Maria Elena Dell'Aquila; Angelo Paradiso; Anna Teti; Nadia Rucci; Stephan Joel Reshkin
Journal:  Mol Biol Cell       Date:  2012-04-11       Impact factor: 4.138

9.  A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.

Authors:  Nicola S Meagher; Linyuan Wang; Peter F Rambau; Maria P Intermaggio; David G Huntsman; Lynne R Wilkens; Mona A El-Bahrawy; Roberta B Ness; Kunle Odunsi; Helen Steed; Esther Herpel; Michael S Anglesio; Bonnie Zhang; Neil Lambie; Anthony J Swerdlow; Jan Lubiński; Robert A Vierkant; Ellen L Goode; Usha Menon; Aleksandra Toloczko-Grabarek; Oleg Oszurek; Sanela Bilic; Aline Talhouk; Montserrat García-Closas; Qin Wang; Adeline Tan; Rhonda Farrell; Catherine J Kennedy; Mercedes Jimenez-Linan; Karin Sundfeldt; John L Etter; Janusz Menkiszak; Marc T Goodman; Paul Klonowski; Yee Leung; Stacey J Winham; Kirsten B Moysich; Sabine Behrens; Tomasz Kluz; Robert P Edwards; Jacek Gronwald; Francesmary Modugno; Brenda Y Hernandez; Christine Chow; Linda E Kelemen; Gary L Keeney; Michael E Carney; Yanina Natanzon; Gregory Robertson; Raghwa Sharma; Simon A Gayther; Jennifer Alsop; Hugh Luk; Chloe Karpinskyj; Ian Campbell; Peter Sinn; Aleksandra Gentry-Maharaj; Penny Coulson; Jenny Chang-Claude; Mitul Shah; Martin Widschwendter; Katrina Tang; Minouk J Schoemaker; Jennifer M Koziak; Linda S Cook; James D Brenton; Frances Daley; Björg Kristjansdottir; Constantina Mateoiu; Melissa C Larson; Paul R Harnett; Audrey Jung; Anna deFazio; Kylie L Gorringe; Paul D P Pharoah; Parham Minoo; Colin Stewart; Oliver F Bathe; Xianyong Gui; Paul Cohen; Susan J Ramus; Martin Köbel
Journal:  Mod Pathol       Date:  2019-06-25       Impact factor: 8.209

10.  HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy.

Authors:  Jessica N McAlpine; Kimberly C Wiegand; Russell Vang; Bridgett M Ronnett; Anna Adamiak; Martin Köbel; Steve E Kalloger; Kenneth D Swenerton; David G Huntsman; C Blake Gilks; Dianne M Miller
Journal:  BMC Cancer       Date:  2009-12-10       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.